SCHEMBL372225

SCHEMBL372225

COc1cc2c(Oc3ccc(N(C(=O)C4(C(N)=O)[C@H](C)[C@@H]4C)c4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.62
AXL P30530 7/20 0.56
EGFR P00533 4/20 0.56
PLK4 O00444 3/20 0.56
AURKA O14965 3/20 0.56
RIPK2 O43353 3/20 0.56
STK10 O94804 3/20 0.56
FYN P06241 3/20 0.56
YES1 P07947 3/20 0.56
LYN P07948 3/20 0.56
SRC P12931 3/20 0.56
FER P16591 3/20 0.56
MAP2K2 P36507 3/20 0.56
CSK P41240 3/20 0.56
ABL2 P42684 3/20 0.56
LIMK1 P53667 3/20 0.56
PTK2 Q05397 3/20 0.56
STK4 Q13043 3/20 0.56
PRKAA1 Q13131 3/20 0.56
TNK1 Q13470 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL372007 1.00 MET (0.62) METAXLEGFRPLK4AURKA
SCHEMBL372302 0.94 MET (0.63) METAXLEGFRPLK4AURKA
SCHEMBL2923405 0.94 MET (0.63) METAXLEGFRPLK4AURKA
SCHEMBL371943 0.94 MET (0.63) METAXLEGFRPLK4AURKA
SCHEMBL372158 0.94 MET (0.63) METAXLEGFRPLK4AURKA
SCHEMBL371939 0.92 MET (0.61) METAXLEGFRPLK4AURKA
SCHEMBL372271 0.92 MET (0.61) METAXLEGFRPLK4AURKA
SCHEMBL371783 0.91 FLT4 (0.52) METAXLEGFRPLK4AURKA
SCHEMBL371886 0.91 MET (0.61) METAXLEGFRPLK4AURKA
SCHEMBL371898 0.90 MET (0.59) METAXLEGFRPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 EP disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 EP disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 EP disclosed
EP-2392565-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2014-03-19 EP disclosed
EP-2392564-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2013-10-23 EP disclosed
EP-2612853-A1 c-Met modulators and methods of use Exelixis Inc. (US) 2013-07-10 EP disclosed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 EP disclosed
EP-2392565-A1 c-Met modulators and methods of use Exelixis Inc. (US) 2011-12-07 EP disclosed
EP-2392564-A1 c-Met modulators and methods of use Exelixis Inc. (US) 2011-12-07 EP disclosed
EP-1673085-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2011-11-09 EP disclosed
EP-2210607-B1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer EXELIXIS INC (US) 2011-08-17 EP disclosed
EP-2213661-B1 c-Met Modulators and Methods of Use EXELIXIS INC (US) 2011-07-20 EP disclosed
EP-2213661-A1 c-Met Modulators and Methods of Use Exelixis Inc. (US) 2010-08-04 EP disclosed
EP-2210607-A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer Exelixis Inc. (US) 2010-07-28 EP disclosed